<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>TB R&#38;D Matters Blog &#187; TB R&amp;D Spotlight Interviews</title>
	<atom:link href="http://www.newtbdrugs.org/blog/category/tb-rd-spotlight-interviews/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.newtbdrugs.org/blog</link>
	<description>Working Towards a Faster Cure for Tuberculosis</description>
	<lastBuildDate>Thu, 23 May 2013 21:18:28 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>Immunotherapeutic Vaccines, TB and China: Interview with Dr. Douglas Lowrie</title>
		<link>http://www.newtbdrugs.org/blog/immunotherapeutic-vaccines-tb-and-china-interview-with-dr-douglas-lowrie/</link>
		<comments>http://www.newtbdrugs.org/blog/immunotherapeutic-vaccines-tb-and-china-interview-with-dr-douglas-lowrie/#comments</comments>
		<pubDate>Thu, 11 Oct 2012 20:29:40 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[Uncategorized]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[clinical trials]]></category>
		<category><![CDATA[drug discovery]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=4175</guid>
		<description><![CDATA[This week we highlight an interview with Dr. Douglas Lowrie, a Senior Research Fellow at Fudan University's Shanghai Public Health Clinical Center in China.   He discusses the extent of the problem of TB in China and innovative research on enhancing TB treatment using immunotherapeutic vaccines.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/immunotherapeutic-vaccines-tb-and-china-interview-with-dr-douglas-lowrie/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Integrating TB and HIV Services at the Community Level</title>
		<link>http://www.newtbdrugs.org/blog/integrating-tb-and-hiv-services-at-the-community-level/</link>
		<comments>http://www.newtbdrugs.org/blog/integrating-tb-and-hiv-services-at-the-community-level/#comments</comments>
		<pubDate>Tue, 19 Jun 2012 19:45:45 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Faces of TB]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[Video]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[collaborations]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[community health worker]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[stigma]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[voices]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3978</guid>
		<description><![CDATA[This week we highlight an interview with Jeannine Uwimana, a public health specialist from the University of the Western Cape and TB/HIV Care Association in South Africa.  She discusses her work in developing models for community-based programs to enhance TB and HIV collaborative activities.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/integrating-tb-and-hiv-services-at-the-community-level/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Community Engagement through Drama</title>
		<link>http://www.newtbdrugs.org/blog/community-engagement-through-drama/</link>
		<comments>http://www.newtbdrugs.org/blog/community-engagement-through-drama/#comments</comments>
		<pubDate>Tue, 17 Apr 2012 17:16:46 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Faces of TB]]></category>
		<category><![CDATA[TB Patient Perspective]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[TB Stigma]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[advocacy]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[community engagement]]></category>
		<category><![CDATA[education]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[social impact]]></category>
		<category><![CDATA[South Africa]]></category>
		<category><![CDATA[tb/hiv]]></category>
		<category><![CDATA[voices]]></category>
		<category><![CDATA[youth empowerment]]></category>

		<guid isPermaLink="false">http://www.newtbdrugs.org/blog/?p=3729</guid>
		<description><![CDATA[Dr. Gill Black is the co-founder and Director of Health and Welfare at The Sustainable Livelihoods Foundation (SLF).  In this inteview, we discuss with Dr. Black one of SLF's groundbreaking projects that uses drama to engage local communities around issues related to TB and HIV/AIDS.  ]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/community-engagement-through-drama/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Podcast Interview with Dr. Edward Nardell</title>
		<link>http://www.newtbdrugs.org/blog/podcast-interview-with-dr-edward-nardell/</link>
		<comments>http://www.newtbdrugs.org/blog/podcast-interview-with-dr-edward-nardell/#comments</comments>
		<pubDate>Tue, 17 May 2011 19:40:27 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[mdr]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2630</guid>
		<description><![CDATA[This week, we feature an interview with Dr. Edward Nardell who is a pulmonologist with a special interest in tuberculosis.  His principal academic appointment is as associate professor of medicine, Harvard Medical School.  In 2002 he joined Partners In Health as Director of Tuberculosis Research. During the interview, we discuss with Dr. Nardell his background and interest in TB, the Airbourne Infections Research (AIR) Facility, his thoughts on the MDR-TB epidemic, and his current research focus.  Additional links to TB R&#038;D News are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/podcast-interview-with-dr-edward-nardell/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Eric Nuermberger</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-eric-nuermberger/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-eric-nuermberger/#comments</comments>
		<pubDate>Tue, 15 Mar 2011 04:16:11 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[JHU]]></category>
		<category><![CDATA[pk/pd studies]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2302</guid>
		<description><![CDATA[In this week''s TB R&#038;D update, the WGND had the opportunity to talk with Dr. Nuermberger on a recent article entitled "PA-824 exhibits time-dependent activity in a murine model of tuberculosis" that we covered in a previous TB R&#038;D Weekly Update.  In the interview, Dr. Nuermberger provides an overview of his present research, key results presented in the article, and <i>in vitro</i> and preclinical testing of TB drug regimens.  Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-eric-nuermberger/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update:  Podcast Interview with Peter Andersen</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-peter-andersen/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-peter-andersen/#comments</comments>
		<pubDate>Tue, 08 Mar 2011 15:07:41 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[TB Treatment]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2272</guid>
		<description><![CDATA[In this week''s TB R&#038;D update, The WGND had the opportunity to talk with Dr. Andersen on a recent article entitled "A multistage tuberculosis vaccine that confers efficient protection before and after exposure" that we covered in a previous TB R&#038;D Weekly Update.  In the interview, Dr. Andersen provides an overview of his present research and the article, possible integration of a vaccine that protects pre- and post- exposure into TB treatment, and the challenges for TB vaccine development.  Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-peter-andersen/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Podcast Interview with Philip Bourne</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-philip-bourne/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-philip-bourne/#comments</comments>
		<pubDate>Tue, 22 Feb 2011 12:00:42 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Early Drug Development]]></category>
		<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[pharma]]></category>
		<category><![CDATA[podcast]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2146</guid>
		<description><![CDATA[In this week''s TB R&#038;D update, The WGND had the opportunity to talk with Dr. Bourne on a recent article published in PLoS Computational Biology in November 2010.  Dr. Philip Bourne is a professor at University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Editor in Chief of PL0S Computational Biology.  In the interview, Dr. Bourne discusses his present research, use of structural bioinformatics to inform drug discovery, and the need for open access in research.  Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-philip-bourne/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>TB R&amp;D Weekly Update: Podcast Interview with Anne Lenaerts</title>
		<link>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-anne-lenaerts/</link>
		<comments>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-anne-lenaerts/#comments</comments>
		<pubDate>Tue, 15 Feb 2011 12:00:58 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[Front Lines of TB R&D]]></category>
		<category><![CDATA[TB Drug Development]]></category>
		<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[WGND Podcast Series]]></category>
		<category><![CDATA[animal models]]></category>
		<category><![CDATA[innovations]]></category>
		<category><![CDATA[publications]]></category>
		<category><![CDATA[r&d]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=2143</guid>
		<description><![CDATA[In this week''s TB R&#038;D update, the WGND had the opportunity to talk with Dr. Lenaerts on a recent article published ahead of print in the Antimicrobial Agents and Chemotherapy journal in December 2010.   Dr. Anne Lenaerts is an associate professor at Colorado State University''s College of Veterinary Medicine and Biomedical Sciences in the Department of Microbiology, Immunology and Pathology.  In the interview, Dr. Lenaerts provides an overview of her present research and the article, key recommendations for use of mouse models for testing TB drugs and the issue of relapse studies.  Also, links to additional news in TB R&#038;D are included.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/tb-rd-weekly-update-podcast-interview-with-anne-lenaerts/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Dr. Michele Miller on TB in Wildlife &#8211; Part Three of Three</title>
		<link>http://www.newtbdrugs.org/blog/dr-michele-miller-on-tb-in-wildlife-part-three-of-three/</link>
		<comments>http://www.newtbdrugs.org/blog/dr-michele-miller-on-tb-in-wildlife-part-three-of-three/#comments</comments>
		<pubDate>Tue, 25 May 2010 13:00:26 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[voices]]></category>
		<category><![CDATA[wildlife]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=846</guid>
		<description><![CDATA[TB R&#038;D Spotlight Interview with Dr. Michele Miller: In part three of our talk with Dr. Michele Miller, the Chief Veterinary Officer and Director of the Center for Conservation Medicine at the Palm Beach Zoo, an expert on tuberculosis in wildlife populations, we discuss the state of funding to stop TB in wild animals.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/dr-michele-miller-on-tb-in-wildlife-part-three-of-three/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Spotlight: Dr. Michele Miller on TB in Wildlife &#8211; Part Two</title>
		<link>http://www.newtbdrugs.org/blog/spotlight-dr-michele-miller-on-tb-in-wildlife-part-two/</link>
		<comments>http://www.newtbdrugs.org/blog/spotlight-dr-michele-miller-on-tb-in-wildlife-part-two/#comments</comments>
		<pubDate>Tue, 18 May 2010 13:00:02 +0000</pubDate>
		<dc:creator>Working Group</dc:creator>
				<category><![CDATA[TB R&D Spotlight Interviews]]></category>
		<category><![CDATA[Voices from the Fight to Stop Tuberculosis]]></category>
		<category><![CDATA[voices]]></category>
		<category><![CDATA[wildlife]]></category>

		<guid isPermaLink="false">http://blog.newtbdrugs.org/?p=843</guid>
		<description><![CDATA[TB R&#038;D Spotlight Interview with Dr. Michele Miller: In part two of our interview, we discuss the impact that TB could have on wildlife populations. Tuberculosis is currently a leading infectious disease in both human and animal populations across the world.  Because it is an older disease, it goes under recognized in all groups – especially wildlife.  While it may not generate as much attention as HIV, or Ebola, it can have greater impact on the balance of the environment and our wildlife populations.]]></description>
		<wfw:commentRss>http://www.newtbdrugs.org/blog/spotlight-dr-michele-miller-on-tb-in-wildlife-part-two/feed/</wfw:commentRss>
		<slash:comments>1</slash:comments>
		</item>
	</channel>
</rss>
